Hormonal
Type 2 diabetes is a complex metabolic disorder driven by a strong genetic predisposition involving at least 75 identified common genetic loci, with heritability further modulated by epigenetic mechanisms such as DNA methylation in response to environmental factors.
Your risk for Type 2 Diabetes is significantly influenced by your genetics, with over 75 specific gene variants linked to the disease. However, this risk is not fixed; it interacts with your environment through epigenetic changes (like DNA methylation). This means that while you cannot change your DNA, you can influence how those genes are expressed through lifestyle factors, potentially mitigating genetic risk.
Type 2 diabetes (T2DM) is a common complex metabolic disorder that has a strong genetic predisposition. During the past decade, progress in genetic association studies has enabled the identification of at least 75 independent genetic loci for T2DM... Environmental factors also have a crucial role in the development of T2DM. These could modulate gene expression via epigenetic mechanisms, including DNA methylation, histone modification and microRNA regulation.
Why this rating
The paper synthesizes large-scale GWAS, meta-analyses, and sequencing studies from multiple consortia.
Source
Recent progress in genetic and epigenetic research on type 2 diabetes
Soo Heon Kwak et al. · Experimental & Molecular Medicine · 2016
DOI 10.1038/emm.2016.7
More from this paper
- Specific rare or low-frequency genetic variants (e.g., in SLC30A8, MTNR1B, PPARG) can have a large functional effect on T2DM risk, with some loss-of-function variants actually protecting against the disease.Good
- Epigenetic modifications, particularly DNA methylation, serve as a mechanism through which environmental factors (such as intrauterine malnutrition, obesity, and diet) influence the development of Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →